Akari Therapeutics, Plc
Akari Therapeutics, Plc (AKTX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
aktx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Akari Therapeutics, Plc (AKTX) measures how much investors pay for each dollar of the company's trailing earnings. AKTX's current PE ratio of N/A is calculated by dividing its stock price of $15.45 by its TTM earnings per share of -$1333.08.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2010 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Akari Therapeutics, PlcYou AKTX | $18M | N/A | — | -$1333.08 |
 CDT Equity Inc. CDT | $4M | N/A | — | -$1177.90 |
 Dermata Therapeutics, Inc. DRMA | $1M | N/A | — | -$8.16 |
 MSP Recovery, Inc. MSPR | $0M | N/A | — | -$359.78 |
 Psyence Biomedical Ltd. PBM | $0M | 14.15x | — | $1.78 |
 Purple Biotech Ltd. PPBT | $0M | N/A | — | -$10992.95 |
 Revelation Biosciences, Inc. REVB | $4M | N/A | — | -$14.36 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-822.15 | — | |
2024-12-31 FY2024 | — | $-3313.97 | — | |
2023-12-31 FY2023 | — | $-4089.91 | — | |
2022-12-31 FY2022 | — | $-11373.28 | — | |
2021-12-31 FY2021 | — | $-16238.80 | — | |
2020-12-31 FY2020 | — | $-40003.79 | — | |
2019-12-31 FY2019 | — | $-36822.30 | — | |
2018-12-31 FY2018 | — | $-51818.18 | — | |
2017-12-31 FY2017 | — | $-94818.31 | — | |
2016-12-31 FY2016 | — | $-80092.70 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Akari Therapeutics, Plc (AKTX) measures how much investors pay for each dollar of the company's trailing earnings. AKTX's current PE ratio of N/A is calculated by dividing its stock price of $15.45 by its TTM earnings per share of -$1333.08.
Frequently asked questions
AKTX pe ratio · 6 questionsAKTX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $15.45 and TTM EPS of -$1333.08. Data sourced from Financial Modeling Prep via AKTX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Akari Therapeutics, Plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09